CLBS Stock : Caladrius Biosciences, Inc. A biopharmaceutical company with a clinical stage is focused on the development as well as commercializing cell therapies that treat disease or promote renewal of tissue damaged. Its candidates for products include HONEDRA which is which is a recipient of SAKIGAKE designation and is currently in Phase II clinical trial for the treatment of ischemia in the critical limbs; XOWNA that is in phase IIb of a clinical trial to test treating coronary microvascular disease and CLBS201 which is an CD34+ cell therapy that is used to treat of patients who are pre-dialysis with the chronic kidney condition. The company was previously called NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June of 2015. Caladrius Biosciences, Inc. was founded in 1980 and is located at Basking Ridge, New Jersey.
Caladrius Biosciences Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| CLBS | -66.67% | -94.23% | -43.45% | -100% |
| S&P | -7.62% | +49.76% | +8.40% | +990% |
Caladrius Biosciences Company Info
NeoStem Inc. is engaged in a platform business managing an autologous commercial adult stem cell bank. It is pioneering collection of stem cells prior to disease and longer-term preservation of stem cells from donors.
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $31.48M | +146.5% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $0.35M | +550.9% |
| Short Term Debt | $0.20M | -31.6% |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -60.8% | +68.3% |
| Return On Invested Capital | -43.9% | -28.0% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$4.02M | -20.2% |
| Operating Free Cash Flow | -$4.00M | -20.7% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 0.55 | 0.49 | 0.39 | 0.23 | -69.3% |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 7.65 | 7.02 | 5.44 | 0.23 | -97.8% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | 6.46 | 6.72 | 6.05 | 7.28 | +85.2% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -44.0% | -23.8% | -26.2% | -64.5% | +68.5% |
| Total Debt | $0.71M | $0.63M | $0.56M | $0.55M | +56.6% |
